HC Wainwright & Co. Reiterates Buy on Actinium Pharmaceuticals, Maintains $4 Price Target
Benzinga Newsdesk 22 hours ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharmaceuticals (AMEX:ATNM) with a Buy and maintains $4 price target.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharmaceuticals (AMEX:ATNM) with a Buy and maintains $4 price target.
